MIF and in situ carcinoma: Overall, our data suggest that overexpression of the MIF cytokine family signature may occur in CD4+ T cells from patients with CIS and that this phenomenon may be implicated in the pathogenesis of the disease, offering the possibility to represent both a diagnostic marker and a therapeutic target.